Advertisement

The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy

  • Siavash Raigani
  • Sonia Cohen
  • Genevieve M. BolandEmail author
Melanoma (RJ Sullivan, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Melanoma

Abstract

Purpose of Review

The recent discovery of effective systemic treatments for melanoma has dramatically improved the prognosis for patients with advanced disease. As a result, the multidisciplinary management of melanoma has evolved significantly. In the past decades surgery was reserved for symptomatic palliation in patients with metastatic melanoma. Today surgical treatment of patients responding to systemic therapies has become an integral part of disease control.

Recent Findings

Current efforts are focused on minimizing the morbidity of surgery (laparoscopic inguinal lymph node dissection, selective completion lymphadenectomy) as well as combining surgery with systemic therapy in novel ways (neoadjuvant targeted and/or immunotherapy, isolated limb infusion/perfusion with systemic immunotherapy).

Summary

This review examines the use of surgery for advanced melanoma in the era predating modern systemic therapy as well as potential applications moving forward.

Keywords

Surgery Metastasectomy Melanoma Targeted therapy Immunotherapy 

Notes

Compliance with Ethical Standards

Conflict of Interest

Siavash Raigani, Sonia Cohen, and Genevieve M. Boland declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. 1.
    Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011;104:111–5.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    •• Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609. The Multicenter Selective Lymphadenectomy Trial (MSLT-I) is a phase 3 trial designed to determine whether identifying patients with clinically occult nodal melanoma metastases via sentinel node biopsy and then performing an immediate completion lymphadenectomy in those patients improves outcomes. Results of the study suggest that sentinel node biopsy and early completion lymphadenectomy do provide survival benefit to patients with intermediate thickness melanoma, most likely because those individuals in the biopsy group with clinically occult metastases at the time of the study were identified and treated, preventing regional recurrence. However, whether completion lymphadenectomy is necessary or whether removal of the sentinel nodes themselves provides adequate therapeutic benefit will be further addressed by MSLT-II (ongoing) CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Boland GM, Gershenwald JE. Sentinel lymph node biopsy in melanoma. Cancer J. 2012;18:185–91.CrossRefPubMedGoogle Scholar
  6. 6.
    Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30:2912–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Faries MB, Thompson JF, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol. 2010;17:3324–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jakub JW, Terando AM, et al. Safety and feasibility of minimally invasive inguinal lymph node dissection in patients with melanoma (SAFE-MILND): report of a prospective multi-institutional trial. Ann Surg. 2016; In pressGoogle Scholar
  9. 9.
    Leiter U, Stadler R, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757–67.CrossRefPubMedGoogle Scholar
  10. 10.
    National Comprehensive Cancer Network. Melanoma. Version 3.2016. Available at: www.nccn.org. Accessed Oct 1, 2016.
  11. 11.
    • Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–17.CrossRefPubMedGoogle Scholar
  12. 12.
    • Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32. These randomized, phase 3 trials demonstrate the efficacy of anti-programmed cell death inhibition (PD-1) in advanced melanoma by significantly improving progression-free and overall survival with less toxicity than inhibition of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Combination therapy with anti PD-1 and CTLA4 agents was shown to be most effective with median patient survival approaching one year. The advent of systemic therapies able to control the progression of advanced disease has introduced new roles for surgical approaches to minimize disease burden in metastatic melanoma CrossRefPubMedGoogle Scholar
  13. 13.
    Abbott AM, Zager JS. Locoregional therapies in melanoma. Surg Clin of North Am. 2014;94:1003–15.CrossRefGoogle Scholar
  14. 14.
    Moller MG, Lewis JM, Dessureault S, et al. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperth. 2008;24:275–89.CrossRefGoogle Scholar
  15. 15.
    Memoral Sloan Kettering Cancer Center. Availble at https://www.mskcc.org/cancer-care/clinical-trials/10-101. Accesses September 30, 2016.
  16. 16.
    Howard JH, Thompson JF, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19:2547–55.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Balch CM, Gershenwald JE. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Robert C, Karaszewska B, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Green DS, Bodman-Smith MD, Dalgleish AG, et al. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol. 2007;156:337–45.CrossRefPubMedGoogle Scholar
  20. 20.
    Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol. 1993;19:985–90.CrossRefPubMedGoogle Scholar
  21. 21.
    Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol. 2003;139:273–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Harpole DH, Johnson CM, Wolfe WG, et al. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 1992;103:743–8.PubMedGoogle Scholar
  23. 23.
    Pogrebniak HW, Stovroff M, Roth JA, et al. Resection of pulmonary metastases from malignant melanoma: results of a 16-year experience. Ann Thorac Surg. 1988;46:20–3.CrossRefPubMedGoogle Scholar
  24. 24.
    Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg. 1995;110:119–28.CrossRefPubMedGoogle Scholar
  25. 25.
    Schuhan C, Muley T, Dienemann H, et al. Survival after pulmonary metastasectomy in patients with malignant melanoma. Thorac Cardiovasc Surg. 2011;59:158–62.CrossRefPubMedGoogle Scholar
  26. 26.
    Panagiotou I, Brountzos EN, Bafaloukos D, et al. Malignant melanoma metastatic to the gastrointestinal tract. Melanoma Res. 2002;12:169–73.CrossRefPubMedGoogle Scholar
  27. 27.
    Agrawal S, Yao TJ, Coit DG. Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol. 1999;6:336–44.CrossRefPubMedGoogle Scholar
  28. 28.
    Morton DL, Ollila DW, Hsueh EC, et al. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin. 1999;49:101–16.CrossRefPubMedGoogle Scholar
  29. 29.
    Martinez SR, Young SE. A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat Rev. 2008;34:614–20.CrossRefPubMedGoogle Scholar
  30. 30.
    Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117:4740–6.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Morton DL, Mozzillo N, Thompson JA, et al. An international, randomized, double-blind, phase 3 study of the specific active immunotherapy agent, Onamelatucel-L (Canvaxin), compared to placebo as post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol. 2006;13:5.CrossRefGoogle Scholar
  32. 32.
  33. 33.
    ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02858921. Accessed November 3, 2016.
  34. 34.
  35. 35.

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Siavash Raigani
    • 1
  • Sonia Cohen
    • 1
  • Genevieve M. Boland
    • 1
    Email author
  1. 1.Division of Surgical Oncology, Massachusetts General HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations